## Giuseppe Malizia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2871871/publications.pdf

Version: 2024-02-01

840585 677027 1,220 22 11 22 citations h-index g-index papers 23 23 23 1637 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Clinical states of cirrhosis and competing risks. Journal of Hepatology, 2018, 68, 563-576.	1.8	302
2	Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology, 1991, 100, 150-159.	0.6	202
3	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Journal of Hepatology, 2019, 71, 265-273.	1.8	138
4	The Systemic Capillary Leak Syndrome: A Case Series of 28 Patients From a European Registry. Annals of Internal Medicine, 2011, 154, 464.	2.0	130
5	Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology, 1995, 108, 145-156.	0.6	83
6	New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatology International, 2018, 12, 34-43.	1.9	79
7	Increased Expression of Leukocyte Function Associated Antigen-1 (LFA-1) and Intercellular Adhesion Molecule-1 (ICAM-1) by Alveolar Macrophages of Patients with Pulmonary Sarcoidosis. Chest, 1991, 100, 910-916.	0.4	54
8	Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. American Journal of Medicine, 2017, 130, 1219.e19-1219.e27.	0.6	53
9	Analysis of Local mRNA Expression for Extracellular Matrix Proteins and Growth Factors Using in situ Hybridization in Fibroproliferative Lung Disorders. Chest, 1991, 99, 55S-56S.	0.4	47
10	Expression of leukocyte adhesion molecules in the liver of patients with chronic hepatitis B virus infection. Gastroenterology, 1991, 100, 749-755.	0.6	38
11	The incidence of esophageal varices in cirrhosis. Gastroenterology, 2001, 120, A2.	0.6	28
12	PROCOLLAGEN TYPE I PRODUCTION BY HEPATOCYTES: A MARKER OF PROGRESSIVE LIVER DISEASE?. Lancet, The, 1987, 330, 1055-1057.	6.3	11
13	Betaâ€blockers in 2016: Still the safest and most useful drugs for portal hypertension?. Hepatology, 2016, 63, 1771-1773.	3.6	11
14	Prognosis research and risk of bias. Internal and Emergency Medicine, 2016, 11, 251-260.	1.0	11
15	Delayed-Onset Superior Mesenteric Artery Syndrome Presenting as Oesophageal Peptic Stricture. Case Reports in Gastroenterology, 2012, 6, 94-102.	0.3	7
16	JC Virus, Helicobacter pylori, and Oesophageal Achalasia: Preliminary Results from a Retrospective Caseâ€"Control Study. Digestive Diseases and Sciences, 2013, 58, 1433-1434.	1.1	6
17	The consequences of COVID-19 pandemic on patients with monoclonal gammopathy–associated systemic capillary leak syndrome (Clarkson disease). Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 626-629.	2.0	6
18	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. Expert Review of Anticancer Therapy, 2016, 16, 1291-1302.	1.1	4

#	Article	IF	CITATIONS
19	Statins in Cirrhosis: The Magic Pill?. Hepatology, 2016, 63, 2047-2049.	3.6	4
20	Refining earlyâ€ <scp>TIPS</scp> criteria requires good quality prognostic studies. Liver International, 2018, 38, 412-414.	1.9	4
21	Sustained response after lamivudine treatment in HBe minus chronic hepatitis B. Journal of Hepatology, 2004, 40, 870-871.	1.8	1
22	An openâ€safety study of dual antiviral therapy in realâ€world patients with chronic hepatitis C. Pharmacoepidemiology and Drug Safety, 2010, 19, 1113-1123.	0.9	1